<DOC>
	<DOC>NCT02292186</DOC>
	<brief_summary>The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.</brief_summary>
	<brief_title>A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Subjects who previously received and tolerated revusiran (ALNTTRSC) in the ALNTTRSC002 study Adequate liver function Not Pregnant or nursing Inadequate renal function Uncontrolled hypertension, ischemic heart disease or clinically significant cardiac arrhythmia Untreated hypo or hyperthyroidism Prior major organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>FAC</keyword>
	<keyword>Amyloid</keyword>
	<keyword>Transthyretin</keyword>
	<keyword>TTR</keyword>
	<keyword>RNAi therapeutic</keyword>
</DOC>